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Prospective Registration and Outcome-Reporting
Bias in Randomized Controlled Trials of Eczema
Treatments: A Systematic Review
Helen Nankervis1, Akerke Baibergenova2, Hywel C. Williams1 and Kim S. Thomas1
We assessed completeness of trial registration and the extent of outcome-reporting bias in published
randomized controlled trials (RCTs) of eczema (atopic dermatitis) treatments by surveying all relevant RCTs
published from January 2007 to July 2011 located in a database called the Global Resource of Eczema Trials
(GREAT). The GREAT database is compiled by searching six bibliographic databases, including EMBASE and
MEDLINE. Out of 109 identified RCTs, only 37 (34%) had been registered on an approved trial register. Only 18
out of 109 trials (17%) had been registered ‘‘properly’’ in terms of submitting the registration before the trial end
date and nominating a primary outcome. The proportion of ‘‘any registered’’ and ‘‘properly registered’’ RCTs
increased from 19% and 10% in 2007 to 57% and 36% in 2011, respectively. Assessment of selective outcome-
reporting bias was difficult even among the properly registered trials owing to unclear primary outcome
description especially with regard to timing. Only 5 out of the 109 trials (5%) provided enough information for
us to be confident that the outcomes reported in the published trial were consistent with the original
registration. Adequate trial registration and description of primary outcomes for eczema RCTs is currently poor.
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INTRODUCTION
Outcome-reporting bias in a clinical study is defined as
selective reporting of a subset of the study findings based on
the significance and direction of the results. Selective
reporting of outcomes has been well recognized in general
medicine trials where around 40–62% of studies have been
found to have at least one primary outcome that was
changed, introduced, or omitted (Dwan et al., 2008). The
effects of such distortion of what was planned in a study are
potentially serious for clinical practice. In their review of the
effects of outcome-reporting bias in systematic reviews,
Kirkham et al. (2010) found that of 42 meta-analyses with a
statistically significant result, 8 (19%) became nonsignificant
after adjusting for outcome-reporting bias and 11 (26%)
would have overestimated the treatment effect by X20%.
The problem of outcome-reporting bias has not been studied
among randomized controlled trials (RCTs) in the field of
dermatology.
One of the main ways of reducing selective outcome-
reporting bias is to require all trial investigators to register
details of their trial in a publicly accessible register before the
trial recruitment starts. Those reading the final trial report can
then go back to the original trial registration to check whether
what was highlighted as the primary outcome measure in the
published report corresponded to that in the original
registration. In 2004, the International Committee of Medical
Journal Editors (ICMJE) initiated a policy requiring investiga-
tors to register their trials into a clinical trial registry before
participant enrollment begins as a condition of publication in
one of their journals (DeAngelis et al., 2004). This policy
came into effect in July 2005. A number of dermatology
journals followed this policy, including the British Journal of
Dermatology and the Journal of Investigative Dermatology in
2005 (Williams and Stern, 2005; Ormerod and Williams,
2005). A number of trial registers sprang up in the early
1990s, containing different core items, culminating in the
World Health Organization (WHO) hosting an International
Clinical Trial Registry Platform of approved trial registries
(http://www.who.int/ictrp/en/, accessed 23 November 2011)
that fulfilled key quality criteria and collected a minimum set
of key study domains. Around the same time, dermatology
journals also encouraged authors to report all of the
important study features included in the Consolidated
Standards of Reporting Trials Statement (http://www.consort-
statement.org/, accessed 23 November 2011).
This study sought to assess the extent to which out-
come-reporting bias is evident in the field of dermatology,
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using published RCTs of eczema treatments in people with
eczema (atopic dermatitis) as an example. The study had
three objectives:
(1) To assess the proportion of eczema treatment RCTs
registered.
(2) To see whether the lack of registration was associated
with differences in risk of bias, sample size, and funding
source.
(3) To assess the level of possible outcome-reporting bias of
the primary outcome in eczema treatment trials.
Our hypotheses were that (1) less than half of eczema
RCTs would have been registered; (2) quality of reporting of
trials without preregistration would be poorer; and (3) even in
the trials that were properly registered, selective outcome-
reporting bias may still exist, i.e., there may be discrepancies
between the primary outcome that was registered and the
primary outcome reported in the published trial report.
RESULTS
A total of 122 eczema RCTs were published between 1
January 2007 and 31 July 2011 and included in the Global
Resource of Eczema Trials (GREAT) database (Figure 1).
Twelve studies were excluded because they had published
abstracts, but it was not possible to identify a full trial
publication. Two publications came from the same study,
with the latter publication being a follow-up of the original
trial (van der Aa et al., 2010). Only the first publication,
describing the original trial, was included in this study.
Levels of registration of eczema treatment trials
Of the remaining 109 included studies, only 37 (34%) had
been registered in any form as shown in the study flowchart
in Figure 1. In 9 of these 37 trials, the trial registration was
done more than a year after the study had been completed
and published (the longest time interval was almost 3 years
after study completion), and thus could not be defined as
‘‘properly registered’’. Only 20 (54%) of the 37 registered
studies indicated their trial registration number in the final
trial publication.
Among the 37 studies with a registered protocol, 18
studies (49%) had ‘‘properly registered’’ according to our
definition. Although there has been an increase in trial
registration from 2007 onward, the proportion of ‘‘properly
registered’’ trials was still low, reaching a maximum of
29% (4/14) in the first half of 2011. The increasing trend in
the proportion of registered eczema treatment trials was
significant (P¼0.003) (Figure 2).
Differences between trials with and without registration
Although registered trials had a larger median sample size of
70 people (interquartile range 37.5–192) compared with 60
people (interquartile range 30–104.5) for trials without
registration, this difference was not statistically significant
(P¼0.405). Nonregistered trials were significantly less likely
to specify their funding source in the subsequent publication
than registered trials (3% vs 30%, P¼0.001), and a post-hoc
analysis looking at choice of comparator showed that
nonregistered trials were no more likely to include a placebo
comparator than registered trials (70% vs 57%, P¼ 0.188).
Overall, the differences in the estimated risk of bias were
not statistically significant, with the exception of allocation
concealment domain, where registered trials scored margin-
ally better: 24% (9/37) were at low risk of bias compared with
8% (6/72) for nonregistered trials, P¼ 0.04 (Figure 3).
Outcome reporting in properly registered trials and their
registration records
The most common discrepancy was missing time-frame
information for measurement of the primary outcome: in
Search result (n = 122)
RCTs in GREAT database and
published between 1 January 2007
and 31 July 2011
RCT with full publication (n = 109)
Excluded (n = 12)
Not properly registered RCTs
(n = 19)
Abstracts only (n = 11)
Follow-up of the same original
trial (n = 1)
Registered RCTs (n = 37)
No primary outcome in the
registration record (n = 1)
RCT was registered after study
completion (n = 18)
Properly registered RCTs (n = 18)
Figure 1. Flowchart of trial selection. GREAT, Global Resource of Eczema
Trials; RCT, randomized controlled trial.
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Figure 2. Proportion of eczema trials that were ‘‘registered’’ and ‘‘properly
registered’’ among those published from January 2007 to July 2011. Total
convenience sample¼ 109 trials.
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8 out of 18 trials, registration records did not state the
timing of the primary outcome measurement. In addition, the
description of the primary outcome was often vague and
unclear: this occurred in 5 out of the 18 ‘‘properly registered’’
trials (Table 1). For example, a primary outcome might be
described as ‘‘efficacy in treating exacerbations’’ or ‘‘stable
remission’’, without further detail as to how this was to
be measured or assessed.
Assessment of outcome-reporting bias among properly
registered trials
The lack of detail and clarity of reporting for the outcomes
of registered trials both from the registration record and from
the published trial report makes the objective of assessing
outcome-reporting bias in eczema treatment trials difficult.
One study introduced a new statistically significant primary
outcome that was not present in the registration record
(original primary outcome was not significant) (Hon et al.,
2007), one study changed the eczema severity score from
SCORAD (Scoring of Atopic Dermatitis) to SASSAD (Six Area
Six Sign Atopic Dermatitis Score) (Gambichler et al., 2009),
and one study changed the time frame for assessment of the
primary outcome from 26 weeks to 4 weeks (Frankel et al.,
2011). None of these latter changes resulted in a significant
result being reported.
DISCUSSION
Main findings
Our study has shown that the proportion of published eczema
RCTs registered on an approved trial registry increased from
19% in 2007 to 57% in 2011. The fact that over half of the
RCTs published in 2011 were registered is cause for some
optimism. However, the proportion of trials that were
‘‘properly registered’’, lodging details of the proposed trial
design before the end of the study, or within 12 months of the
recorded trial start date and indicating the primary outcome
in the registration, was considerably lower. Taking into
account that our definition of ‘‘properly registered’’ was a
very generous one, this is a particularly sobering result.
Overall, of the 109 eczema RCTs examined, only 5 trials
were registered a priori, gave sufficient detail about the
primary outcome to judge adherence to the original registra-
tion record, and reported the primary outcome in line with
the original registration (or included an explanation as to why
this had changed). That only 5% of the recent eczema trials
were registered correctly and with enough detail to assess
outcome-reporting bias for the primary outcome, coupled
with the observation that nonregistered or incompletely
registered studies fail to highlight the shortcomings of such
omissions, is bad science and a potential waste of resources
(Chalmers, 1990; Chalmers and Glasziou, 2009).
Even when investigators had preregistered their trial,
46% failed to include details of their trial registration in the
published trial report, suggesting that investigators and
journal editors do not yet appreciate the importance of such
information in their trial reports. The revised version of the
Consolidated Standards of Reporting Trials Statement state-
ment for guidance on the reporting of RCTs now explicitly
recommends that details of trial registration be reported fully,
and this should improve trial reporting in the future
(http://www.consort-statement.org/, accessed 23 November
2011).
The fact that some investigators chose to preregister their
trial could be an indicator of trial quality, and this was
explored using the four key domains known to be associated
with a high risk of bias (Higgins and Altman, 2008). In this
sample of eczema RCTs, there was a suggestion that trial
quality might be improved in registered trials, but this was
only significant for the domain of allocation concealment,
and is possibly limited by the modest sample size of our
survey.
With regard to the hypothesis that eczema trials are
subject to outcome-reporting bias, we found some evidence
of discrepancies between trial registration and trial reports.
However, these were generally as a result of unclear and
nonspecific trial registration information rather than clear
signs of biased reporting. In general, the number of correctly
registered trials was so low that firm conclusions are difficult.
Greater efforts could certainly be made to provide more
detail regarding the primary outcome and its timing within
trial registry records. It is hoped that reviews such as this one
will be helpful in informing trialists of the importance and
relevance of detailed information being lodged in the trial
registries. It is also important that changes to the registration
record subsequent to trial commencement be fed into the trial
registries in a timely manner, in order to maintain trans-
parency throughout. The concept of threaded publications,
enabling the tracking of clinical research studies from
inception and the linking of all resulting publications,
Proportion of trials at risk of bias:
registered trials
38
24
32
67.5
42
8 88
58 0
4
54 15
56 22 22
31
13.5
49
76
62
19
19
0
0Method of randomization
Allocation concealment
Blinding
Missing participant data
Proportion of trials at risk of bias:
nonregistered trials
Low risk
Method of randomization
Allocation concealment
Blinding
Missing participant data
Unclear risk High risk
Low risk Unclear risk High risk
Figure 3. Risk of bias among trials with and without registration (% at low,
unclear, and high risk of bias).
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including the raw data where this is available, is another
emerging tool to ensure consistency between what was
planned and what was done (Faure and Hrynaszkiewicz,
2011).
Comparison with other studies
Overall, the rates for registration of eczema RCTs were lower
than those reported for other surveys of general medical
journals and larger specialities. Mathieu et al. (2009) looked
at RCTs indexed in 2008 in 10 general medicine and
specialty journals (cardiology, rheumatology, and gastroen-
terology); of the 323 included trials, 45.5% were adequately
registered, 13.9% were registered after the completion of
study, and 12% were registered with no or unclear
description of the primary outcome.
A systematic review of studies examining the impact of
selective outcome reporting in RCTs identified five studies
and compared the trial publication with trial registration
record. It found that between 40 and 62% of trials had at least
one primary outcome that had been changed, introduced, or
omitted (Dwan et al., 2008). These rates are higher than the
rates found in the current study, which might be a reflection
of improvements in trial reporting subsequent to the
introduction of the ICMJE policy. Alternatively, it is possible
that higher rates of outcome-reporting bias would have been
found if more of the eczema trials had been registered, thus
allowing a comparison of the published results with the trial
registration. It is conceivable that to date only the better-
quality eczema trials have been registered appropriately.
Strengths and limitations of our study
This study used the GREAT database to identify and assess all
eczema trials published over the past four and a half years.
Using this global collection of appraised eczema trials
allowed for the speedy completion of this review and the
easy identification of all relevant RCTs that had been
identified through a sensitive search of several bibliographic
databases. Including all trials on a particular topic, rather
than just those reported in specific journals or as a random
sample of published trials, meant that our study is less open to
selection bias. Eczema is one of the most common skin
conditions and is commonly researched. More than 250 RCTs
of eczema treatments have been published in the past 10
years alone (www.greatdatabase.org.uk, accessed August
2011). It is possible that for other common skin conditions,
the proportion of trials registered and possible outcome-
reporting bias may be different, which makes the results of
this study difficult to generalize to the field of dermatology
research as a whole.
Our definition of a properly registered trial as one that was
registered before the end of the study was a generous one,
given that the ICMJE requires that all clinical trials need to be
registered in an approved publicly accessible clinical trial
register before patient recruitment begins. It is likely that the
bottom-line figure of only 5% of all recent eczema trials that
have been properly registered would have been even worse if
this more stringent definition had been applied, although in
many cases it was impossible for us to tell when recruitment
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began and when the study ended. On the point of timing, it is
worth noting that some trialists registered their trials after the
study had been completed, which defeats the whole purpose
of prospective trial registration as a tool to prevent cheating.
Our sample size was relatively small, which affected the
overall precision of our estimates of ‘‘properly registered’’
RCTs.
Finally, this review limited its scope to an evaluation of the
primary outcomes assessed in trials. Others have reported
considerable outcome-reporting bias for secondary outcomes,
particularly in relation to the preferential reporting of
statistically significant secondary outcomes (Chan et al., 2004).
Implications of our findings
The introduction of mandatory trial registration as required by
the Journal of Investigative Dermatology is a great opportu-
nity to improve the quality and truthfulness of trial reporting,
which will in turn lead to better clinical decision-making by
reducing the prevalence of spurious and misleading results
and reduction in research wastage (Chalmers and Glasziou,
2009). Although the publication bias of whole studies is
relatively well known, the phenomenon of selective out-
come-reporting bias within studies is possibly less well
understood within the dermatology clinical community
(Chan and Altman, 2005).
Ideally, deviations from the trial registration record should
be described in the published articles so that readers can
interpret the results in full knowledge of the changes made.
For the full benefits of trial registration to be realized, it is
important that all investigators, funders, journal editors, peer
reviewers, readers, and the public have an active role in
making full use of trial registration information and high-
lighting the need for transparent trial reporting. Journal
referees and readers of clinical trials especially should make
more use of scrutinizing trial registries to note whether a
clinical trial has truly been registered prospectively, and
whether the outcomes reported in the paper are consistent
with what was planned. Those conducting systematic reviews
are also in a good position to check on and comment on trial
registration of included trials, and to assess whether selective
outcome-reporting bias was likely to have occurred.
Conclusion
Adequate trial registration for eczema RCTs is poor.
Registration of all trials in a publicly accessible database is
a critical step toward ensuring the transparent reporting of
clinical trial results that affect health care.
MATERIALS AND METHODS
A systematic search for RCTs of eczema treatments that had been
published since January 2007 was conducted. For all identified trials,
the WHO International Clinical Trial Registry Platform was searched
for proof of approved trial registration.
Searching for published eczema trials
We used a convenience sample of all published eczema trials
that have been captured in the GREAT database (http://www.
greatdatabase.org.uk, accessed August 2011). This open-access
resource brings together information on all RCTs of eczema
treatments published since the beginning of 2000 in order to
facilitate future methodological research and systematic reviews.
The GREAT database uses the Cochrane Highly Sensitive Search
Strategy for identifying randomized trials in MEDLINE: sensitivity-
maximizing version (2008 revision); Ovid format (Lefebvre et al.,
2009) combined with the terms eczema, atopic eczema, atopic
dermatitis, infantile eczema, childhood eczema, neurodermatitis,
and Besnier’s prurigo. Similar searches combined with the same list
of eczema terms are used to search the EMBASE, CINAHL, AMED,
and LILACS databases. The Cochrane Library (www.thecochraneli-
brary.co.uk) and the Cochrane Skin Group Specialised register are
also searched using the same eczema terms. The search runs from
the beginning of 2000 and is updated regularly.
Inclusion criteria for the present study
Allowing 1.5 years from the ICMJE policy of trial registration coming
into effect, we included all eczema treatment RCTs contained in the
GREAT database that had been published between 1 January 2007
and 31 July 2011. Whether or not these trials contained safety data
was not relevant to this study and thus did not form part of the
inclusion or exclusion criteria. We excluded RCTs that were
published in abstract form only. If both an abstract and a full paper
were found, only the full paper was included. Details of all trials
included in this study are listed as an online table (Supplementary
Table S1 online).
Identifying trial registration
If the trial registration ID number was stated in the final publication,
we used this number to find the trial registration. Where this number
was not stated, we tried to obtain the registration record using the
WHO International Clinical Trial Registry Platform, which searches
a number of different trial registries throughout the world (see
Table 2).
Table 2. The list of data providers of the WHO ICTRP
search portal1
Australian New Zealand Clinical Trials Registry (ANZCTR)
Chinese Clinical Trial Register (ChiCTR)
Clinical Research Information Service (CRiS), Republic of Korea
ClinicalTrials.gov
Clinical Trials Registry—India (CTRI)
Cuban Public Registry of Clinical Trials (RPCEC)
German Clinical Trials Register (DRKS)
Iranian Registry of Clinical Trials (IRCT)
ISRCTN.org
Japan Primary Registries Network (JPRN)
Pan African Clinical Trial Registry (PACTR)
Sri Lanka Clinical Trials Registry (SLCTR)
The Netherlands National Trial Register (NTR)
1Source: World Health Organization website http://www.who.int/ictrp/
search/data_providers/en/index.html (last accessed 12 August 2011).
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Two people searched for trial registration independently (AB and
HN) using a combination of key words: ‘‘eczema’’ or ‘‘atopic
dermatitis’’, plus keywords describing the trial’s interventions, such
as ‘‘pimecrolimus’’ or ‘‘probiotics’’. All registration records that met
the search criteria were reviewed to find the one that matched the
published trial using key information supplied in the record (e.g., the
name of principal investigator, funding source, and trial design).
As a rule, we did not spend more than 15–20 minutes looking
for each record, on the grounds that trial registration should be easy
and quick to identify.
Distinguishing between ‘‘registered’’ and
‘‘properly registered’’ trials
All eczema treatment trials in the sample from the GREAT database
registered on the WHO International Clinical Trial Registry Platform
were included in the number of ‘‘registered’’ trials. This provides the
overall level of trial registration for eczema trials, regardless of
whether or not they fulfilled the guidelines for trial registration
correctly. In addition, we identified a ‘‘properly registered’’ subset of
these trials, which could be used to assess outcome-reporting bias.
We defined ‘‘properly registered’’ trials as those trials in which the
primary outcome was explicitly stated in the registration document
and in which the trial was registered not later than the end of the
study (last patient visit). In cases in which the start of participant
enrollment was stated, but an end date was not recorded, we
considered a trial to be properly registered if the registration was
lodged within 12 months of the study start date. Only ‘‘properly
registered’’ trials were included in the evaluation of outcome-
reporting bias.
To take into account the amendments and possible changes that
could have taken place after initial trial registration but before data
lock, we used the URL provided on the WHO trial registration
webpage to go to the source record for each of the ‘‘properly
registered’’ trials in the primary register and looked for additional
information or updates regarding the trial.
Comparison between registered and nonregistered trials
We compared registered and nonregistered trials with respect
to several characteristics, including the number of participants
randomized, funding, and quality of reporting. The quality of
reporting was assessed using the Cochrane Collaboration’s
risk of bias tool (Higgins and Altman, 2008) in four different
domains: randomization method, allocation concealment, blinding
(of participants, personnel, and outcome assessors), and complete-
ness of outcome data. Each trial was assessed for high,
low, or unclear risk of bias for each of these domains using the
revised terms suggested in the updated version of the Cochrane
Handbook (Higgins et al., 2011) to improve interpretation of the
risk of bias.
Comparison of primary outcome between publication and
registration among properly registered trials
For each properly registered trial, we reviewed and compared
primary outcomes reported in the publication with those stated in
the registration. Both the primary outcome and the time frame for
analysis were recorded. We chose to limit the review of outcome
bias to the primary outcome for this first study, because of the
importance of primary outcomes in determining the success or
otherwise of a study and because detailed analysis of secondary
outcomes was beyond the scope of our available resources.
We defined a discrepancy as follows: (1) when the primary
outcome in the published report was different from that in the
registration and (2) when the time frame for assessing the primary
outcome in the published report was different from the registration.
Sample size calculation
Sample size was determined by the number of available trials that
had been published since the introduction of the ICMJE guidelines.
We also estimated that we would need around 100 studies in order
to estimate the proportion of registered studies (which we hypothe-
sized would be around 50%) to within 10 percentage points. All eczema
RCTs published in the past four and a half years were included.
Data assessment
The following comparisons were made:
(1) The proportion of trials registered.
(2) The proportion of trials properly registered versus the propor-
tion registered in any form.
(3) The proportion of registered trials with the registration number
stated in the final publication.
(4) The average sample size of registered trials versus nonregistered
trials.
(5) The proportion of trials that declared a funding source.
(6) The proportion of registered versus nonregistered trials with a
placebo comparator.
(7) The number of trials with a low/unclear/high risk of bias for
each of the four domains for registered trials versus non-
registered trials.
(8) The number of properly registered trials with a missing time
frame for the primary outcome.
(9) The number of properly registered trials with a vague and/or
unclear primary outcome.
Statistical analysis
We used frequency and percentages for categorical variables, and
mean with SD or median and interquartile ranges for continuous
variables, as appropriate. Proportions were compared using w2 and
Fisher’s exact tests where appropriate. Trends over time were assessed
using w2 for trend. Continuous variables were compared using
t-test and Mann–Whitney U-test for nonparametric data. Po0.05
(two-tailed) was considered statistically significant. All statistics
were calculated using SPSS version 16 (IBM, www.ibm.com) except
w2 for trend, which was calculated using StatsDirect (Stats Direct,
www.statsdirect.com). The protocol for this study was posted on the
Centre of Evidence Based Dermatology website (http://www.nottin-
gham.ac.uk/dermatology) at the beginning of the study in September
2011 and before data analysis.
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